Applied Therapeutics Inc

NASDAQ:APLTUnited States

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing a pipeline of product candidates against validated molecular targets in indications of high unmet medical need. The Company’s molecular target is aldose reductase (AR), an enzyme that converts glucose to sorbitol under oxidative stress conditions. Its product candidates include AT-007, AT-001, AT-003 and AT-104. The Company’s AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. AT-001 is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), fatal fibrosis of the heart. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). AT-104 is a dual selective PI3K inhibitor in preclinical development for T Cell Acute Lymphoblastic Leukemia (T-ALL).

Contact Information

Headquarters

545 5TH AVENUE, SUITE 1400NEW YORK, NY, United States 10017

Phone

212-220-9319

Fax

302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer, Founder

Shoshana Shendelman

Chief Commercial Officer

Adam Hansard

Chief Medical Officer

Riccardo Perfetti

Lead Independent Director

Teena Lerner

Independent Director

Leslie Funtleyder